/PCSA

PCSA Stock - Processa Pharmaceuticals, Inc.

Q: What is the analyst price target for PCSA?

Analyst price target information is not currently available for PCSA.

Q: What is PCSA's market cap?

Market capitalization information is not currently available for PCSA.

Healthcare|Biotechnology|NASDAQ

$3.78-3.08%

$0.12 (-3.08%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+138.1%upside

Target: $9.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PCSA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.09

52W High$27.00

52W Low$2.75

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	$-882,062
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-12,051,206	$-11,457,061	$-27,525,431	$-12,133,543	$-15,136,859
Net Income	$-11,850,118	$-11,121,520	$-27,424,229	$-11,427,534	$-19,039,736
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-96.75	$-212.00	$-42.50	$-373.00	$-1269.25

Company Overview

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

1 Bullish0 Neutral/Bearish

Price Targets

Average Target

↑ 111.6% Upside

Now

Low

Average

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
April 25th 2024	H.C. Wainwright	Initiation	Buy	$8

Earnings History & Surprises

PCSA

Beat Rate

50%

Last 18 quarters

Avg Surprise

-246.4%

EPS vs Estimate

Beats / Misses

9/9

Last 12 quarters

Latest EPS

$-1.75

Q4 2025

EPS Surprise History

Q1 24

+85.0%

$-0.24vs$-1.60

Q2 24

+5.9%

$-1.11vs$-1.18

Q3 24

-3.1%

$-1.01vs$-0.98

Q4 24

-3.0%

$-1.03vs$-1.00

Q1 25

+19.6%

$-0.74vs$-0.92

Q2 25

+61.0%

$-0.30vs$-0.77

Q3 25

-8.7%

$-0.25vs$-0.23

Q4 25

+12.5%

$-1.75vs$-2.00

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Mar 19, 2026	$-1.50	—	—	—
Q4 2025	Nov 6, 2025	$-2.00	$-1.75	+12.5%	✓ BEAT
Q3 2025	Aug 7, 2025	$-0.23	$-0.25	-8.7%	✗ MISS
Q2 2025	May 8, 2025	$-0.77	$-0.30	+61.0%	✓ BEAT
Q1 2025	Mar 20, 2025	$-0.92	$-0.74	+19.6%	✓ BEAT
Q4 2024	Oct 30, 2024	$-1.00	$-1.03	-3.0%	✗ MISS
Q3 2024	Aug 13, 2024	$-0.98	$-1.01	-3.1%	✗ MISS
Q2 2024	May 10, 2024	$-1.18	$-1.11	+5.9%	✓ BEAT
Q1 2024	Mar 29, 2024	$-1.60	$-0.24	+85.0%	✓ BEAT
Q4 2023	Nov 13, 2023	$-0.10	$-1.60	-1500.0%	✗ MISS
Q3 2023	Aug 10, 2023	$-3.00	$-2.00	+33.3%	✓ BEAT
Q2 2023	May 15, 2023	$-5.60	$-3.60	+35.7%	✓ BEAT
Q1 2023	Mar 30, 2023	$-5.00	$-7.00	-40.0%	✗ MISS
Q4 2022	Nov 8, 2022	$-6.80	$-7.40	-8.8%	✗ MISS
Q3 2022	Aug 12, 2022	$-0.20	$-6.40	-3100.0%	✗ MISS
Q2 2022	May 12, 2022	$-4.80	$-4.00	+16.7%	✓ BEAT
Q1 2022	Mar 30, 2022	$-3.60	$-4.20	-16.7%	✗ MISS
Q4 2021	Nov 12, 2021	$-4.20	$-3.80	+9.5%	✓ BEAT
Q3 2021	Aug 12, 2021	$-3.00	$-4.00	-33.3%	✗ MISS

Frequently Asked Questions about PCSA

What is PCSA's current stock price?

Processa Pharmaceuticals, Inc. (PCSA) is currently trading at $3.78 per share. The stock has moved -3.08% today.

What is the analyst price target for PCSA?

The average analyst price target for PCSA is $9.00, based on 1 analyst.

What sector is Processa Pharmaceuticals, Inc. in?

Processa Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is PCSA's market cap?

Processa Pharmaceuticals, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.

Does PCSA pay dividends?

No, Processa Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.